Serum HER-2/neu concentrations were evaluated in 172 healthy subjects, 176 primary and 55 metastatic breast cancer patients, employing a new automated assay (Bayer Immuno 1™ serum HER-2/neu). Using 13 ng/mL as the cutoff, abnormal HER-2/neu serum levels were found in 8% (14/176) of primary and 50.9% (28/55) of metastatic breast cancer patients.
Both in primary and metastatic breast cancer a significant relationship was found with the stage of the disease when serum HER-2/neu was considered as a categorized variable (p=0.0003 and p=0.02, respectively), but not when it was taken as a continuous variable (p=0.247 and p=0.146, respectively). Moreover, we evaluated the correlation between Immuno 1™ HER-2/neu and Oncogene Research Products ELISA assay in 53 normal subjects, 46 primary and 34 metastatic breast cancer patients. The correlation was relatively good (p<0.0001), although substantial differences could be found in single cases. The Immuno 1™ assay was also evaluated for the first time in breast cancer tissue. The method, which showed good performance both in terms of imprecision and linearity, was used to measure HER-2/neu protein in 140 cytosol samples from primary breast cancer tissue and in homogenates from 40 matched cases. The correlation between the two matrixes was very close (p<0.0001). By contrast, no correlation was found between serum and matched cytosol (p=0.101) or ho-mogenate samples (p=0.511).
RossJ.S., FletcherJ.A.The Her-2/neu oncogene: prognostic factor, predictive factor and target for therapy.Cancer Biol1999; 9: 125–38.
2.
DowsettM., CookeT., EllisI.Assessment of HER2 status in breast cancer: why, when and how?Eur J Cancer2000; 36: 170–6.
3.
YamauchiH., StearnsV., HayesD.F.When is a tumor marker ready for prime time? A case study of C-erbB-2 as a predictive factor in breast cancer.J Clin Oncol2001; 19: 2334–56.
4.
CarneyW.P., HamerP.J., PetitD.Detection and quantitation of the human neu oncoprotein.J Tumor Markers Oncol1991; 6: 53–72.
5.
LeitzelK., TeramotoY., SampsonE.Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.J Clin Oncol1992; 10: 1436–43.
6.
NaritaT., FunahashiH., SatohY., TakagiH.C-erbB-2 protein in the sera of breast cancer patients.Breast Cancer Res Treat1992; 24: 97–102.
7.
KathR., HoffkenK., OtteC.The neu-oncogene product in serum and tissue of patients with breast carcinoma.Ann Oncol1993; 4: 585–90.
8.
FontanaX., FerrariP., NamerM., PeyssonR., SalanonC., BussiereF.C-erb-B2 gene amplification and serum level of C-erb-B2 oncoprotein at primary breast cancer diagnosis.Anticancer Res1994; 14: 2099–104.
9.
IsolaJ.J., HolliK., OksaH., TeramotoY., KallioniemiO-P. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer.Cancer1994; 73: 652–8.
10.
KandlH., SeymourL., BezwodaW.R.Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer.Br J Cancer1994; 70: 739–42.
11.
KrainerM., BrodowiczT., ZeillingerR.Tissue expression and serum levels of Her-2/neu in patients with breast cancer.Oncology1997; 54: 475–81.
12.
MolinaR., JoJ., FilellaX.c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.Breast Cancer Res Treat1998; 51: 109–19.
13.
LeitzelK., TeramotoY., KonradK.Elevated serum c-erb-2 antigen levels and decreased response to hormone therapy of breast cancer.J Clin Oncol1995; 13: 1129–35.
14.
YamauchiH., O'NeillA., GelmanR.Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.J Clin Oncol1997; 15: 2518–25.
15.
HayesD.F., CirrincioneC., CarneyW.Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer (abstract).Proc Am Soc Oncol1993; 12: 58 (abstract).
16.
LiptonA., AliS.M., LeitzelK.Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.Proc ASCO2000; 19: 71a.
17.
RevillionF., HebbarM., BonneterreJ., PeyratJ.P.Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients.Eur J Cancer1996; 32A: 231–4.
18.
HarrisL.N., TrockB., BerrisM., Esteva-LorenzoF., PaikS.The role of C-erb-B-2 extracellular domain (ECD) in predicting response to chemotherapy in breast cancer patients.Proc ASCO1996; 15: 108.
19.
ColomerR., MonteroS., LluchA.Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.Clin Cancer Res2000; 6: 2356–62.
20.
FehmT., MaimonisP., WeitzS., TeramotoY., KatalinicA., JägerW.Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients.Breast Cancer Res Treat1997; 43: 87–95.
21.
MethaR.R., McDermottJ.H., HiekenT.J.Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.J Clin Oncol1998; 16: 2409–16.
22.
PegramM.D., LiptonA., HayesD.F.Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.J Clin Oncol1998; 16: 2659–71.
23.
EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer.Eur J Cancer1980; 16: 1513–6.
24.
National Committee for Clinical Laboratory Standards EP 15-P.User demonstration of performance for precision and accuracy; proposed guideline:NCCLS1998.
25.
WuY., KhanH., ChillarR., VadgamaJ.V.Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer.Int J Oncol1999; 14: 1021–37.
26.
MielkeS., MedenH., RaabT., WuttkeW., KuhnW.Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum.Anticancer Res1997; 17: 3125–8.
27.
MedenH., MielkeS., MarxD., WuttkeW., KuhnW.Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations.Anticancer Res1997; 17: 3075–8.
28.
StreckfusC., BiglerI., DellingerT., DaiX., KingmanA., ThigpenJ.T.The presence of soluble C-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.Clin Cancer Res2000; 6: 2363–70.
DittadiR., GionM.More about: prognostic importance of low c-erbB2 expression in breast tumors.J Natl Cancer Inst2000; 92: 1443.
34.
Eppenberg-CastoriS., KuengW., BenzC.Prognostic and predictive significance of erbB-2 breast tumor levels measured by enzyme immunoassay.J Clin Oncol2001; 19: 645–56.
35.
SuganoK., UshiamaM., FukutomiT., TsudaI., KitohT., OhkuraH.Combined measurement of the c-erbB-2 protein in breast carcinoma tissue and sera is useful as a sensitive tumor marker for monitoring tumor relapse.Int J Cancer2000, 89: 329–36.
